The administration of intranasal medications alleviated nasal symptoms and was safe for treating seasonal and perennial allergic rhinitis (AR) in children, although they appeared less effective than ...

A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared ...

Intranasal drug delivery systems offer a non-invasive approach to transporting therapeutic agents directly to the central nervous system by circumventing the blood–brain barrier. These systems exploit ...

Wednesday, Oragenics Inc. (NYSE:OGEN) announced the completion of its spray-dried formulation and filling in the nasal device for its lead candidate, ONP-002, for concussion. Oragenics is a ...